The FDA 510(k) clearance covers performing Centiloid scaling for positron emission tomography (PET)-based amyloid imaging analysis and quantification. Available with MIMneuro – a vendor-neutral solution – the new Centiloid scale tool can help clinicians more confidently determine the density of amyloid plaque in a patient’s brain, according.
Centiloid scaling with MIMneuro offers a standardized, quantitative metric to assist healthcare providers in confidently estimating amyloid plaque density, one key aspect of this debilitating disease.
The new imaging tool is winning clearance at the same time that pharmaceutical companies are releasing new therapies onto the market to help treat the condition. As amyloid-targeting therapies continue to show meaningful results against Alzheimer’s disease, PET imaging can help clinicians more confidently determine a patient’s amyloid status.
【MORE】